UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

PD-L1 Expression in Clear Cell Renal Cell Carcinoma: An Analysis of Nephrectomy and Sites of Metastases

Journal of Cancer, 2014-01, Vol.5 (3), p.166-172

2014

Volltextzugriff (PDF)

5 Mechanism based targeted therapy for hereditary leiomyomatosis and renal cell cancer (HLRCC) and sporadic papillary renal cell carcinoma: interim results from a phase 2 study of bevacizumab and erlotinib

European journal of cancer (1990), 2014-11, Vol.50, p.8-8

2014

Volltextzugriff (PDF)

Abstract No. 234 Long-Term Survival After Percutaneous CT and Contrast-Enhanced Ultrasound-Guided Microwave Ablation of Pathologically Proven Renal Cell Carcinoma

Journal of vascular and interventional radiology, 2024-03, Vol.35 (3), p.S106-S106

2024

Volltextzugriff (PDF)

Abstract No. 231 Long-Term Survival After Percutaneous Image-Guided Ablation of Oligometastatic Renal Cell Carcinoma

Journal of vascular and interventional radiology, 2024-03, Vol.35 (3), p.S105-S105

2024

Volltextzugriff (PDF)

Transforming the Perioperative Treatment Paradigm in Non-Metastatic RCC—A Possible Path Forward

Kidney Cancer, 2017-07, Vol.1 (1), p.31-40

2017

Volltextzugriff (PDF)

1690O NKT2152, a novel oral HIF-2α inhibitor, in participants (pts) with previously treated advanced clear cell renal carcinoma (accRCC): Preliminary results of a phase I/II study

Annals of oncology, 2024-09, Vol.35, p.S1011-S1012

2024

Volltextzugriff (PDF)

1887P Adjuvant everolimus (EVE) in patients (pts) with completely resected very high-risk renal cell cancer (RCC) and clear cell histology: Results from the phase III SWOG S0931 (EVEREST) trial

Annals of oncology, 2023-10, Vol.34, p.S1015-S1015

2023

Volltextzugriff (PDF)

LBA4 Adjuvant nivolumab plus ipilimumab (NIVO+IPI) vs placebo (PBO) for localized renal cell carcinoma (RCC) at high risk of relapse after nephrectomy: Results from the randomized, phase III CheckMate 914 trial

Annals of oncology, 2022-09, Vol.33, p.S1430

2022

Volltextzugriff (PDF)

LBA67 Phase III randomized study comparing perioperative nivolumab (nivo) versus observation in patients (Pts) with renal cell carcinoma (RCC) undergoing nephrectomy (PROSPER, ECOG-ACRIN EA8143), a National Clinical Trials Network trial

Annals of oncology, 2022-09, Vol.33, p.S1432-S1433

2022

Volltextzugriff (PDF)

An investigation of risk factors for renal cell carcinoma by histologic subtype in two case‐control studies

International journal of cancer, 2013-06, Vol.132 (11), p.2640-2647

2013

Volltextzugriff (PDF)

Nivolumab + ipilimumab (NIVO + IPI) adjuvant versus placebo dans le carcinome rénal localisé à haut risque de récidive après néphrectomie : résultats de l’étude de phase 3 randomisée Checkmate 914 (CM914)

Progrès en urologie. Formation médicale continue, 2022-11, Vol.32 (3), p.S88-S88

2022

Volltextzugriff (PDF)

TEP/TDM au 89ZR-DFO-Girentuximab pour l’imagerie des carcinomes rénaux à cellules claires–résultats de l’étude de phase III ZIRCON

Progrès en urologie. Formation médicale continue, 2023-11, Vol.33 (3), p.S66

2023

Volltextzugriff (PDF)

[89Zr]Zr-DFO-girentuximab pour l’imagerie par TEP/TDM des cancers du rein à cellules claires – Résultats de l’étude de phase 3 ZIRCON

Médecine nucléaire : imagerie fonctionelle et métabolique, 2024-03, Vol.48 (2), p.48-48

2024

Volltextzugriff (PDF)

Racial Disparity of Epidermal Growth Factor Receptor Expression in Prostate Cancer

Journal of clinical oncology, 2004-12, Vol.22 (23), p.4725-4677

2004

Volltextzugriff (PDF)

Prognostic Factors in Renal Cell Carcinoma

Seminars in oncology, 2006-10, Vol.33 (5), p.563-575

2006

Volltextzugriff (PDF)

SERUM LEVELS OF SHED HER2/NEU PROTEIN IN MEN WITH PROSTATE CANCER CORRELATE WITH DISEASE PROGRESSION

The Journal of urology, 2005-12, Vol.174 (6), p.2174-2177

2005

Volltextzugriff (PDF)

Impact of pathologic tumor characteristics in patients with sarcomatoid renal cell carcinoma

Journal of clinical oncology, 2011-03, Vol.29 (7_suppl), p.343-343

2011

Volltextzugriff (PDF)

Use of the UCLA-integrated staging system (UISS) to predict survival after sunitinib treatment for patients with metastatic renal cell carcinoma

Journal of clinical oncology, 2010-05, Vol.28 (15_suppl), p.4593-4593

2010

Volltextzugriff (PDF)

Use of chromosome 9p status to identify a subset of high-risk localized renal cell carcinoma

Journal of clinical oncology, 2009-05, Vol.27 (15_suppl), p.5090-5090

2009

Volltextzugriff (PDF)

Use of CA9 gene single nucleotide polymorphisms to predict prognosis and treatment response of metastatic renal cell carcinoma

Journal of clinical oncology, 2009-05, Vol.27 (15_suppl), p.5003-5003

2009

Volltextzugriff (PDF)

Brain metastasis from renal cell carcinoma: Presentation, recurrence, survival and implications for systemic therapy

Journal of clinical oncology, 2008-05, Vol.26 (15_suppl), p.5097-5097

2008

Volltextzugriff (PDF)

Re: Presence of Tumor Necrosis is Not a Significant Predictor of Survival in Clear Cell Renal Cell Carcinoma: Higher Prognostic Accuracy of Extent Based Rather Than Presence/Absence Classification

The Journal of urology, 2009-12, Vol.182 (6), p.2979-2981

2009

Volltextzugriff (PDF)

Racial disparity of epidermal growth factor receptor (EGFR) expression in prostate cancer (PC)

Journal of clinical oncology, 2004-07, Vol.22 (14_suppl), p.4556-4556

2004

Volltextzugriff (PDF)

Racial disparity of epidermal growth factor receptor (EGFR) expression in prostate cancer (PC)

Journal of clinical oncology, 2004-07, Vol.22 (14_suppl), p.4556-4556

2004

Volltextzugriff (PDF)

GENDER SPECIFIC CYTOGENETIC SIGNATURES CAN DISTINGUISH BETWEEN ONCOCYTOMA AND CHROMOPHOBE RENAL CELL CARCINOMA

European urology supplements : official journal of the European Association of Urology, 2008, Vol.7 (3), p.135-135

2008

Volltextzugriff (PDF)

1 – 25 von 89

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(81)
Mit Volltextzugriff
(70)

Publikationsform

Artikel
(89)

Sprache

Englisch
(86)
Französisch
(3)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)
... seit 90 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

PD-L1 Expression in Clear Cell Renal Cell Carcinoma: An Analysis of Nephrectomy and Sites of Metastases

5 Mechanism based targeted therapy for hereditary leiomyomatosis and renal cell cancer (HLRCC) and sporadic papillary renal cell carcinoma: interim results from a phase 2 study of bevacizumab and erlotinib

Abstract No. 234 Long-Term Survival After Percutaneous CT and Contrast-Enhanced Ultrasound-Guided Microwave Ablation of Pathologically Proven Renal Cell Carcinoma

Abstract No. 231 Long-Term Survival After Percutaneous Image-Guided Ablation of Oligometastatic Renal Cell Carcinoma

Transforming the Perioperative Treatment Paradigm in Non-Metastatic RCC—A Possible Path Forward

1690O NKT2152, a novel oral HIF-2α inhibitor, in participants (pts) with previously treated advanced clear cell renal carcinoma (accRCC): Preliminary results of a phase I/II study

1887P Adjuvant everolimus (EVE) in patients (pts) with completely resected very high-risk renal cell cancer (RCC) and clear cell histology: Results from the phase III SWOG S0931 (EVEREST) trial

LBA4 Adjuvant nivolumab plus ipilimumab (NIVO+IPI) vs placebo (PBO) for localized renal cell carcinoma (RCC) at high risk of relapse after nephrectomy: Results from the randomized, phase III CheckMate 914 trial

LBA67 Phase III randomized study comparing perioperative nivolumab (nivo) versus observation in patients (Pts) with renal cell carcinoma (RCC) undergoing nephrectomy (PROSPER, ECOG-ACRIN EA8143), a National Clinical Trials Network trial

An investigation of risk factors for renal cell carcinoma by histologic subtype in two case‐control studies

Nivolumab + ipilimumab (NIVO + IPI) adjuvant versus placebo dans le carcinome rénal localisé à haut risque de récidive après néphrectomie : résultats de l’étude de phase 3 randomisée Checkmate 914 (CM914)

TEP/TDM au 89ZR-DFO-Girentuximab pour l’imagerie des carcinomes rénaux à cellules claires–résultats de l’étude de phase III ZIRCON

[89Zr]Zr-DFO-girentuximab pour l’imagerie par TEP/TDM des cancers du rein à cellules claires – Résultats de l’étude de phase 3 ZIRCON

Racial Disparity of Epidermal Growth Factor Receptor Expression in Prostate Cancer

Prognostic Factors in Renal Cell Carcinoma

SERUM LEVELS OF SHED HER2/NEU PROTEIN IN MEN WITH PROSTATE CANCER CORRELATE WITH DISEASE PROGRESSION

Impact of pathologic tumor characteristics in patients with sarcomatoid renal cell carcinoma

Use of the UCLA-integrated staging system (UISS) to predict survival after sunitinib treatment for patients with metastatic renal cell carcinoma

Use of chromosome 9p status to identify a subset of high-risk localized renal cell carcinoma

Use of CA9 gene single nucleotide polymorphisms to predict prognosis and treatment response of metastatic renal cell carcinoma

Brain metastasis from renal cell carcinoma: Presentation, recurrence, survival and implications for systemic therapy

Re: Presence of Tumor Necrosis is Not a Significant Predictor of Survival in Clear Cell Renal Cell Carcinoma: Higher Prognostic Accuracy of Extent Based Rather Than Presence/Absence Classification

Racial disparity of epidermal growth factor receptor (EGFR) expression in prostate cancer (PC)

Racial disparity of epidermal growth factor receptor (EGFR) expression in prostate cancer (PC)

GENDER SPECIFIC CYTOGENETIC SIGNATURES CAN DISTINGUISH BETWEEN ONCOCYTOMA AND CHROMOPHOBE RENAL CELL CARCINOMA

Suchergebnisse filtern